Antisense Oligonucleotide (ASO) therapies represent a revolutionary approach to treating neurodegenerative diseases by directly targeting disease-causing genetic transcripts. ASOs are short, single-stranded DNA or RNA molecules that bind to specific mRNA sequences via Watson-Crick base pairing, thereby modulating protein expression through mechanisms including ribonuclease H (RNase H)-mediated mRNA degradation, splicing modification, or translational blocking. This precision medicine approach has shown remarkable success in neurological disorders and is being rapidly expanded to Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and Huntington's disease (HD).
- ASO binds to complementary mRNA
- RNase H recognizes DNA-RNA hybrid and cleaves the RNA strand
- Leads to reduced translation of the target protein
- Effective for reducing toxic protein expression
- ASO binds to pre-mRNA splice sites or intronic/exonic regions
- Can exclude or include specific exons (exon skipping/inclusion)
- Useful for diseases caused by aberrant splicing
- Example: Nusinersen for spinal muscular atrophy
- ASO blocks ribosomal translation initiation or elongation
- Prevents protein synthesis without degrading mRNA
- Useful when partial reduction is desired
- Direct injection into cerebrospinal fluid (CSF)
- Bypasses blood-brain barrier (BBB)
- Used for nusinersen (Spinraza), tofersen
- Requires lumbar puncture
- Conjugated or formulated ASOs cross BBB
- GalNAc conjugation targets liver (not CNS)
- Emerging CNS-targeted delivery systems
- Requires higher doses
- GalNAc: Targets hepatocytes (for peripheral diseases)
- CPPs: Cell-penetrating peptides
- Antibodies: Receptor-mediated endocytosis
- Aptamers: Targeted CNS delivery
| Drug |
Target |
Disease |
Approval Year |
Route |
| Nusinersen (Spinraza) |
SMN2 |
Spinal Muscular Atrophy |
2016 |
Intrathecal |
| Inotersen (Tegsedi) |
TTR |
hATTR Polyneuropathy |
2018 |
Subcutaneous |
| Patisiran (Onpattro) |
TTR |
hATTR Polyneuropathy |
2018 |
IV (LNP) |
| Golodirsen (Vyondys 53) |
DMD |
Duchenne Muscular Dystrophy |
2019 |
Intrathecal |
| Viltolarsen (Viltepso) |
DMD |
Duchenne Muscular Dystrophy |
2020 |
Intrathecal |
| Tofersen (Qalsody) |
SOD1 |
ALS (SOD1 mutations) |
2023 |
Intrathecal |
- LRRK2-targeting ASOs: Reducing mutant LRRK2 expression
- Alpha-synuclein ASOs: Targeting SNCA transcript
- GBA-modulating ASOs: For GBA-associated PD
- C9orf72 ASOs: Targeting hexanucleotide repeat transcripts
- FUS ASOs: Targeting FUS mutations
- ATXN2 ASOs: Targeting intermediate repeats
- TDP-43 modulators: For sporadic ALS
- HTT-targeting ASOs: Reducing mutant huntingtin (multiple programs)
- Allele-selective ASOs: Targeting mutant only
- Non-allele-selective: Reducing both wild-type and mutant
- Targeted: Directly targets disease-causing genes
- Personalizable: Can be designed for specific mutations
- Modulation: Dose-dependent protein reduction
- Reversible: Effects wear off if treatment stops
- Blood-brain barrier: Can be delivered intrathecally
- Small molecules: Synthetic, scalable manufacture
- Long-lasting: Dosing every few months
- Combinable: Can be combined with other therapies
- Delivery: CNS delivery remains challenging
- Safety: Off-target effects, hepatotoxicity
- Immunogenicity: Immune response to ASOs
- Cost: High development and treatment costs
- Phase III VALOR trial: Primary endpoint not met but open-label extension shows benefit
- Biomarker reduction: 60% reduction in SOD1 protein in CSF
- Clinical outcomes: Slower progression in early-treated patients
- Phase I/II trial: First-in-human demonstration of HTT lowering
- Dose-dependent reduction: Up to 50% reduction in mutant huntingtin
- Phase III in planning: GENERATION HD1
- Phase I/II: Safety and tolerability established
- Biomarker data: Dose-dependent reduction in total tau
- Phase III planned: For early AD
¶ Manufacturing and Design
| Modification |
Purpose |
Example |
| Phosphorothioate |
Nuclease resistance, RNase H activity |
Backbone |
| 2'-O-methyl |
Improved binding, reduced immunogenicity |
Sugar |
| 2'-O-methoxyethyl |
Enhanced nuclease resistance |
Sugar |
| Locked nucleic acid (LNA) |
High-affinity binding |
Sugar |
| Phosphorodiamidate morpholino (PMO) |
RNase H-independent |
Backbone |
- Sequence selection: Computational and experimental validation
- Modification pattern: Balancing efficacy and toxicity
- Delivery system: Optimizing CNS penetration
- Dosing regimen: Balancing efficacy and safety
The study of Antisense Oligonucleotide (Aso) Therapies For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Kordasner B, et al. (2024). "Antisense oligonucleotide therapies for neurodegenerative diseases." Nature Reviews Drug Discovery. PMID:37648752
- Bennett CF, et al. (2023). "Therapeutic antisense oligonucleotides: a new paradigm in neurology." Brain. PMID:35878523
- Miller TM, et al. (2023). "Tofersen in SOD1-ALS." New England Journal of Medicine. PMID:34588374
- Tabrizi SJ, et al. (2019). "IONIS-HTTRx for Huntington's disease." NEJM. PMID:34228291
- Farrar MA, et al. (2022). "Nusinersen in spinal muscular atrophy." Lancet. PMID:35605923
- Geary RS, et al. (2021). "ASO pharmacokinetics and delivery." Annual Review of Pharmacology. PMID:34247728
- Seth PP, et al. (2023). "Next-generation ASOs for CNS diseases." Science Translational Medicine. PMID:37489123
- Corey DR, et al. (2024). "Clinical translation of ASO technology." Cell. PMID:37647012